Your browser doesn't support javascript.
loading
High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules.
Xu, Huixiong; Zhang, Yifeng; Wu, Hongxun; Zhou, Ning; Li, Xing; Pineda, John P; Zhu, Yun; Fu, Huijun; Ying, Ming; Yang, Shufang; Bao, Jiandong; Yang, Lulu; Zhang, Bingjie; Guo, Lehang; Sun, Liping; Lu, Feng; Wang, Hanxiang; Huang, Ying; Zhu, Tiantong; Wang, Xiaonan; Wei, Qing; Sheng, Chunjun; Qu, Shen; Lv, Zhongwei; Xu, Dong; Li, Qian; Dong, Yongling; Qin, Jianwu; Cheng, Tong; Xing, Mingzhao.
Afiliação
  • Xu H; Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, School of Medicine, Tongji University, Shanghai, China.
  • Zhang Y; The Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Wu H; Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Zhou N; Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, School of Medicine, Tongji University, Shanghai, China.
  • Li X; The Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Pineda JP; Departments of Endocrinology, Ultrasound and Pathology, JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
  • Zhu Y; Lisen Imprinting Diagnostics Inc, Wuxi, Jiangsu, China.
  • Fu H; Lisen Imprinting Diagnostics Inc, Wuxi, Jiangsu, China.
  • Ying M; Lisen Imprinting Diagnostics Inc, Wuxi, Jiangsu, China.
  • Yang S; Departments of Endocrinology, Ultrasound and Pathology, JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
  • Bao J; The Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Yang L; Department of Pathology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Zhang B; Departments of Ultrasound and Endocrinology, Taizhou People's Hospital, Taizhou, Jiangsu, China.
  • Guo L; Departments of Ultrasound and Endocrinology, Taizhou People's Hospital, Taizhou, Jiangsu, China.
  • Sun L; Department of Endocrinology, Taizhou Third People's Hospital, Taizhou, Jiangsu, China.
  • Lu F; Departments of Endocrinology, Ultrasound and Pathology, JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
  • Wang H; Department of Pathology, Nanjing First Hospital, Nanjing, Jiangsu, China.
  • Huang Y; Departments of Endocrinology, Ultrasound and Pathology, JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
  • Zhu T; Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, School of Medicine, Tongji University, Shanghai, China.
  • Wang X; The Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Wei Q; Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, School of Medicine, Tongji University, Shanghai, China.
  • Sheng C; The Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Qu S; Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, School of Medicine, Tongji University, Shanghai, China.
  • Lv Z; The Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Xu D; Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University Cancer Center, Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, School of Medicine, Tongji University, Shanghai, China.
  • Li Q; The Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Dong Y; Department of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
  • Qin J; Department of Ultrasound, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
  • Cheng T; Lisen Imprinting Diagnostics Inc, Wuxi, Jiangsu, China.
  • Xing M; The Thyroid Research Center of Shanghai, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
J Clin Oncol ; 41(6): 1296-1306, 2023 02 20.
Article em En | MEDLINE | ID: mdl-36378996
ABSTRACT

PURPOSE:

To explore the novel diagnostic value of epigenetic imprinting biomarkers in thyroid nodules. PATIENTS AND

METHODS:

A total of 550 patients with fine-needle aspiration (FNA)-evaluated and histopathologically confirmed thyroid nodules were consecutively recruited from eight medical centers. Quantitative chromogenic imprinted gene in situ hybridization (QCIGISH) was used to assess the allelic expression of imprinted genes SNRPN and HM13, on the basis of which a diagnostic grading model for thyroid nodules was developed. The model was retrospectively trained on 124 postsurgical thyroid samples, optimized on 32 presurgical FNA samples, and prospectively validated on 394 presurgical FNA samples. Blinded central review-based cytopathologic and histopathologic diagnoses were used as the reference standard.

RESULTS:

For thyroid malignancy, the QCIGISH test achieved an overall diagnostic sensitivity of 100% (277/277), a specificity of 91.5% (107/117; 95% CI, 86.4 to 96.5), a positive predictive value (PPV) of 96.5% (95% CI, 94.4 to 98.6), and a negative predictive value (NPV) of 100% in the prospective validation, with a diagnostic accuracy of 97.5% (384/394; 95% CI, 95.9 to 99.0). QCIGISH demonstrated a PPV of 97.8% (95% CI, 94.7 to 100) and NPV of 100%, with a diagnostic accuracy of 98.2% (111/113; 95% CI, 95.8 to 100), for indeterminate Bethesda III-V thyroid nodules. QCIGISH demonstrated a PPV of 96.6% (95% CI, 91.9 to 100) and a NPV of 100%, with a diagnostic accuracy of 97.5% (79/81; 95% CI, 94.2 to 100), for Bethesda III-IV. For Bethesda VI, QCIGISH showed a 100% (184/184) accuracy.

CONCLUSION:

This imprinting biomarker-based test can effectively distinguish malignant from benign thyroid nodules. The high PPV and NPV make the test both an excellent rule-in and rule-out diagnostic tool. With such a diagnostic performance and its technical simplicity, this novel thyroid molecular test is clinically widely applicable.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Nódulo da Glândula Tireoide Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide / Nódulo da Glândula Tireoide Idioma: En Ano de publicação: 2023 Tipo de documento: Article